G-CSF/PEG-G-CSF Market Size, Share, Trends, Development Strategies, Competitive Scenario and Segmentation Analysis
The persuasive Global G-CSF/PEG-G-CSF Market report suggests that the key market players are making moves like product launches, joint ventures, developments, mergers and acquisitions which has influence on the market and Healthcare industry as a whole and also affecting the sales, import, export, revenue and CAGR values. The market data analysed and evaluated in this market report makes achieve business goals and objectives in preset time frame. Painstakingly analysed market segmentation aspect provides a clear idea about the product consumption based on numerous factors ranging from type, application, deployment model, end user to geographical region.
An international Global G-CSF/PEG-G-CSF Market survey report additionally encompasses predictions utilizing a practical arrangement of uncertainties and techniques. With this market report study, key opportunities in the market and influencing factors are provided which is useful to take the business to the highest level.
Data Bridge Market Research analyzes that the global G-CSF/ PEG-G-CSF market is expected to reach the value of USD 5,685.40 million by 2030, at a CAGR of 5.5% during the forecast period. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.
Download PDF Sample Report (Including Graphs, Charts, and List of Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-g-csf-peg-g-csf-market&Shri
The rise in cancer prevention in developed nations and governments’ conscious efforts to promote early diagnosis and treatment have boosted the global market for biosimilar G-CSF sales. The market will experience significant growth as a result of the approved biosimilars Grafeel, Colstim, Neukine, and Filcad, which are also affordable and easily accessible in developing nations. The number of cancer patients is rising in China and India, which is likely to expand the global market. Therefore, using biosimilars rather than the original biologics helps patients pay less for healthcare, which raises demand in the global G-CSF biosimilars sales market. The prices of individual biosimilars are higher than those of generic drugs because of the intricate biological manufacturing processes used to create them.
Granulocyte colony-stimulating factor (G-CSF) is a medication used to treat neutropenia. This is a disease in which the number of white blood cells is lower than average and is caused by some forms of chemotherapy. The main types of G-CSF are lenograstim (Granocyte), filgrastim (Neupogen, zarzio, nivestim, accofil), long-acting (pegylated) filgrastim (pegfilgrastim, neulasta, pelmeg, ziextenco), and lipegfilgrastim (lonquex). Lenograstim is a glycosylated recombinant therapeutic agent that is chemically similar or identical to naturally occurring human granulocyte colony-stimulating factor (G-CSF). Various products include tablets and capsules and treat cancer, blood disorders, growth hormone deficiency, and chronic and autoimmune diseases.
Drivers
- Growing incidences of blood cancers and cancer diseases
Cancer is a general term for many diseases that can affect any part of the body. Other terms used for cancer are malignant tumors and neoplasm. One of the characteristics of cancer is the rapid formation of abnormal cells that grow beyond normal limits and can invade neighboring parts of the body and spread to other organs; the latter process is called metastasis. Extensive metastases are the leading cause of cancer death.
Filgrastim is a granulocyte colony-stimulating factor (GCSF) that helps increase the number of neutrophils in the blood. Filgrastim and pegfilgrastim are highly used to increase white blood cells after cancer chemotherapy or radiation therapy.
- Increasing cases of febrile neutropenia
Febrile neutropenia refers to fever during significant neutropenia. If a patient is neutropenic, their risk of infection may be higher than usual, and the severity of a particular infection may also be higher. Febrile neutropenia is the most common life-threatening complication of cancer treatment; its treatment is often an oncological emergency.
Febrile neutropenia is neutropenia accompanied by fever. Neutropenia refers to a decrease in the concentration of neutrophils in the blood. Neutrophils are a type of white blood cell that help fight infections as part of the immune system. The Infectious Diseases Society of America defines neutropenia as an absolute neutrophil count (ANC) of less than 1500 cells/mm3. The risk of infection and neutropenic fever increases dramatically with severe neutropenia, defined as an absolute neutrophil count (ANC) of less than 500 cells/mm3. Fever is defined as a single oral temperature greater than or equal to 101° Fahrenheit (38.3° Celsius) or a persistent temperature greater than or equal to 100.4° Fahrenheit (38.0° Celsius) or greater for one hour or longer.
Recent Developments
- In July 2018, Accord Healthcare, a subsidiary of Intas Pharmaceuticals Ltd., launched a pegfilgrastim biosimilar across Europe after being given Green Light for Pelgraz® (pegfilgrastim) by CHMP (Committee for Medicinal Products for Human Use). This product launched helped the company to expand their business across Europe.
- In March 2022, Kashiv Biosciences announced the approval of its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen by U.S. Food and Drug Administration (FDA). The product is marketed under the proprietary name RELEUKO.
Increasing incidence of neutropenia is expected to drive the market’s growth rate
The increasing incidence of neutropenia, a condition marked by low neutrophil levels, is a significant driver for the G-CSF (Granulocyte Colony-Stimulating Factor) and PEG-G-CSF (Pegylated Granulocyte Colony-Stimulating Factor) market. Neutropenia commonly occurs as a side effect of chemotherapy and certain diseases, necessitating treatments to stimulate the production of white blood cells. G-CSF and PEG-G-CSF are used in such cases to enhance the body’s ability to produce neutrophils, leading to a higher demand for these medications.
Major Players
Data Bridge Market Research recognizes the following companies as the major G-CSF PEG-G-CSF market players in G-CSF PEG-G-CSF market are USV Private Limited (India), Viatris Inc. (U.S.), Biocon (India), Fresenius Kabi AG (Germany), Hangzhou Jiuyuan Gene Engineering Co., Ltd. (China), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Sandoz International GmbH (Germany), Apotex Inc. (Canada), Cadila Pharmaceuticals (India)
To Gain More Insights into the Market Analysis, Browse the Summary of the Research Report@ https://www.databridgemarketresearch.com/reports/global-g-csf-peg-g-csf-market?Shri
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the this research report
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the market
- Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
Top Key Topics Covered:
- Strategic Imperatives
- Factors Creating Pressure on Growth
- The Strategic Imperative
- Growth Opportunities Fuel the Growth Pipeline Engine
- Research Methodology
- Scope and Segmentation
- Research Context and Scope of Analysis
- Segmentation
- Other Techniques for This Research Report Management
- Growth Opportunity Analysis
- Growth Drivers
- Growth Restraints
- Introduction
- The Impact of the COVID-19 Pandemic and Post
- Future Growth
- Innovation Ecosystem
Continued…
G-CSF/ PEG-G-CSF Market Scope
GLOBAL G-CSF / PEG-G-CSF MARKET, BY INDICATION
- Neutropenia
- Oncology
- Chronic And Autoimmune Diseases
- Blood Disorders
- Growth Hormone Deficiency
- Others
On the basis of indication the global G-CSF/PEG-G-CSF is further segmented into neutropenia, oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency and others.
GLOBAL G-CSF / PEG-G-CSF MARKET, BY DOSAGE
- Mono
- Combination
On the basis of dosage the global G-CSF/PEG-G-CSF is further segmented into mono and combination.
GLOBAL G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION
- Intravenous
- Subcutaneous
On the basis of route of administration the global G-CSF/PEG-G-CSF is further segmented into intravenous and subcutaneous.
GLOBAL G-CSF / PEG-G-CSF MARKET, BY PACKAGING
- Single Use Vials
- Pre Filled Syringes
On the basis of packaging the global G-CSF/PEG-G-CSF is further segmented into single use vials and pre filled syringes.
GLOBAL G-CSF / PEG-G-CSF MARKET, BY END USER
- Hospitals & Clinics
- Research & Academic Institutes
- Ambulatory Surgical Centers
- Others
On the basis of end user the global G-CSF/PEG-G-CSF is further segmented into hospitals and clinics, research & academic institutes, ambulatory surgical centers and others.
GLOBAL G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
Browse Detailed Summary of Research Report with TOC: https://www.databridgemarketresearch.com/toc/?dbmr=global-g-csf-peg-g-csf-market&Shri
Some of the Most Important Questions Scrutinized in the Business Intelligence Report:
- What are the key growth parameters for this global market during the forecast period?
- Which key players are expected to hold the largest market share over the forecast period?
- Who are the leading vendors and manufacturers in this market?
- What are the key strategies adopted by leading players in the market for business development and geographical expansion?
- Which end-use industries can trigger high demand in the market over the forecast period?
- What are the key segments in this market?
- Which regional player will have anticipated leading the global market in terms of size?
- What is the impact of the novel coronavirus pandemic?
- Which obstacles must new players overcome in order to occupy a major position?
Top DBMR Healthcare Reports:
Cerebrospinal Fluid (CSF) Management Market – Industry Trends and Forecast to 2029
Europe G-CSF/PEG-G-CSF Market – Industry Trends and Forecast to 2030
Asia-Pacific G-CSF/ PEG-G-CSF Market – Industry Trends and Forecast to 2030
https://www.databridgemarketresearch.com/reports/global-cardasil-treatment-market?Shri
https://www.databridgemarketresearch.com/reports/global-aestheticcosmetic-lasers-market?Shri
https://www.databridgemarketresearch.com/reports/global-yeast-infection-market?Shri
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Editor Details
-
Company:
- The Wire Times
